Search Results

Rottapel is a Senior Scientist at the Princess Margaret Cancer Centre where he holds the Amgen Chair for Cancer Research. University, the NIH and UCLA, he pursued his postdoctoral studies with Allan Bernstein at the Lunenfeld Research Rottapel’s research interests lies in the elucidation of signal transduction pathways in cancer, immune Robert Rottapel on the web The Rottapel Lab Ontario Institute for Cancer Research University of Toronto

Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule G Proteins and GPCRs in Cancer Department of Pharmacology, School of Medicine, and Associate Director for Basic Science at the Moores Cancer His research team has pioneered the study of G proteins and G protein coupled receptors (GPCRs) in human Silvio Gutkind on the web Gutkind Lab – UC San Diego Moores Cancer Center Gutkind Lab publications Pubmed LinkedIn Twitter UCSD Moores Cancer Center Dr.

Research, 2014) and GPCRs (Feigin, et al., PNAS, 2014) in breast cancer pathogenesis, using mouse models They also discussed his research on cell polarity and its role in cancer progression, his work on G-protein Mike's Research on Cell Polarity and GPCRs in Cancer Mike shared his research on cell polarity and its GPCR Targeted Drugs and Gene Regulation in Cancer Cells Mike presented research on the effect of GPCR-targeted GPCRs and Cancer Immune Modulation Yamina and Mike had a discussion about their research on GPCRs, specifically

- present: Researcher associate, Netherlands Brain Bank" Cheng-Chih Hsiao on the web LinkedIn ReseachGate Institute for Diabetes and Cancer, Helmholtz Centre Munich, Germany, 2. " About Anastasia Georgiadi "Head of Junior Group Endocrine Pharmacology, Institute of Diabetes and Cancer Professional Background Since 2021 Group Leader, Institute for Diabetes and Cancer, Helmholtz Diabetes Centre, Munich 2018 - 2021 Project Team Leader, Institute for Diabetes and Cancer, Helmholtz Diabetes

Potent inhibitors of ADO signaling are currently being tested in cancer patients, including in randomized About John Stagg "John Stagg is a Professor of Pharmacy at Université de Montréal and researcher at the CHUM Research Centre. John Stagg on the web University of Montréal Québec Cancer Consortium The University of Montreal Hospital Research Centre Pubmed LinkedIn Dr.

Discover how GPR65 reshapes our understanding of GPCR signaling and its role in cancer, with Dr. unique academic journey—from early interests in medicine to his pivot toward pharmacology and GPCR research His research centers on the beta-2 adrenergic receptor and GPR65 , a proton-sensing receptor with promising implications in cancer biology. Yamina underscores the therapeutic potential of GPR65, especially in the context of cancer immunotherapy

Trejo’s research program is to gain a thorough and mechanistic understanding of processes that control cell signaling by protease-activated receptors (PARs) and the impact on vascular inflammation and cancer Trejo’s research has focused on PAR1, which has important functions in hemostasis, thrombosis, inflammation , and cancer and is an important drug target. How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research

University of Utah School of Medicine in Salt Lake City, UT, and an investigator with the Huntsman Cancer Ben’s research focuses on Smoothened and other class F GPCRs which play essential roles in embryonic development and in cancer. Ben studied developmental and cancer signaling as a postdoctoral fellow with Philip Beachy at Stanford How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research

Home → Flash News → Disrupting VIPR2 dimerisation halts breast cancer spread—could TM3-4 peptides be the next breakthrough in targeted cancer therapy? dimerisation-of-the-vip-receptor-vipr2-is-essential-to-its-binding-vip-and-g%CE%B1i-proteins%2C-and-to-its-functions-in-breast-cancer-cells drgpcr Published on May 12, 2025 Category GPCR Weekly News Disrupting VIPR2 dimerisation halts breast cancer spread—could TM3-4 peptides be the next breakthrough in targeted cancer therapy?

A large component of his work is centered around dysregulated signaling in cancer and the development of novel mechanism-based cancer therapies. Silvio Gutkind on the web Gutkind Lab – UC San Diego Moores Cancer Center Gutkind Lab publications More J Silvio Gutkind on LinkedIn Gutkind Lab on Twitter UCSD Moores Cancer Center Dr. How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research

Learn about Celtarys Research through the Dr. GPCR Ecosystem. Visit Website About Celtarys Research Celtarys Research develops and commercializes new chemical tools Lucía from Celtarys Research Sep 17 4 min read 1 2 3 4 5 Our Partnership Dr. to welcome Celtarys Research to its partner ecosystem. , CEO of Celtarys Research.

In this episode, Silvio discusses G protein signaling in the context of cancer, immunotherapies, and J Silvio Gutkind on LinkedIn Gutkind Lab – UC San Diego Moores Cancer Center Gutkind Lab publications Gutkind Lab on Pubmed Gutkind Lab on Twitter UCSD Moores Cancer Center Dr. How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research

GPCR Ecosystem and beyond About Monserrat Avila Zozaya "My doctoral research was focused on investigating the cellular effects of missense lung cancer-mutations in the G-protein-coupled receptor Autoproteolysis-Inducing I am currently a postdoctoral researcher fellow in Dr. Kathleen Caron's laboratory at UNC. My research focuses on understanding the molecular mechanisms of adhesion GPCRs (aGPCRs) in lymphatic

was focused on investigating the cellular effects of missense lung cancer-mutations in the G-protein-coupled Sciences, University of Alabama at Birmingham (UAB), Birmingham, Alabama, USA 5 O'Neal Comprehensive Cancer Van Meir pursued postdoctoral work at the Ludwig Institute for Cancer Research in San Diego and joined Van Meir has developed novel therapeutic approaches for cancer using oncolytic adenoviruses and anti-angiogenic novel medicines for cancer treatment."

At the end of his studies, he was awarded the Pfizer Prize for undergraduate research. At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional At the NIH he was the recipient of the coveted NIH ‘Bench-to-Bedside’ Translational Research Grant Award Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based This research stream is now forming the basis of a new technology-based start-up company, HeptOME , to

At the end of his studies, he was awarded the Pfizer Prize for undergraduate research. At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional At the NIH he was the recipient of the coveted NIH ‘Bench-to-Bedside’ Translational Research Grant Award Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based This research stream is now forming the basis of a new technology-based start-up company, HeptOME , to

At the end of his studies, he was awarded the Pfizer Prize for undergraduate research. At the MRC he developed novel prostate cancer therapeutics based upon his research into GPCR pluridimensional At the NIH he was the recipient of the coveted NIH ‘Bench-to-Bedside’ Translational Research Grant Award Stuart’s current research, in the Receptor Biology Lab, focuses on the development of novel GPCR-based This research stream is now forming the basis of a new technology-based start-up company, HeptOME , to

Michel Bouvier is a professor of Biochemistry and Molecular Medicine and the CEO of the Institute for Research in Immunology and Cancer ( IRIC ) at the Université de Montréal. In 1989, he returned to Montréal as a professor of biochemistry and a scholar of the Medical Research Since 2001, he holds the Canada Research Chair in Signal Transduction and Molecular Pharmacology. He has supervised the research work of 75 graduate students and 40 post-doctoral fellows.

Guillaume Sandoz's group in 2019 as a postdoctoral research scientist at Université Côte d‘Azur, France Sabbagh undertook post-doctoral fellowships at the Ontario Cancer Institute and the University of Toronto disorders and cancer at Paraza Pharma Inc. in Montreal. Department of Biochemistry and Molecular Medicine, Institute for Research in Immunology and Cancer (IRIC the development of innovative treatments for a range of diseases, including psychiatric disorders and cancer

GPCR Podcast Strategic Partners Exploring Career Paths in GPCR Research with Dr. After completing his Ph.D., he pursued research in genetics of metabolic regulation at the Institute Since 2021, Jacek has been working at Novo Nordisk at its research sites in the UK (Oxford) and the US of method development, integrity, and honesty in scientific research. their research interests and achievements, particularly in the field of GPCR.

During my Ph.D. at the International Max Planck Research School “The Leipzig School of Human Origins” Since 2014, I have led a research group at the Rudolf Schönheimer Institute of Biochemistry in Leipzig Our ultimate goal is to understand their role in immune cell function and cancer cell metabolism. " Dr Yamina expressed interest in attending a meeting about GPCRs and metabolism in the UK, but was unsure for the GPCR University, with the goal of providing a central hub for researchers in the field.

Michel Bouvier is a professor of Biochemistry and Molecular Medicine and the CEO of the Institute for Research in Immunology and Cancer ( IRIC ) at the Université de Montréal. In 1989, he returned to Montréal as a professor of biochemistry and a scholar of the Medical Research Since 2001, he holds the Canada Research Chair in Signal Transduction and Molecular Pharmacology. He has supervised the research work of 75 graduate students and 40 post-doctoral fellows.

Weill Cornell Graduate School of Medical Sciences in New York City, studying epigenetic changes in cancer During her postdoctoral training at New York University School of Medicine, her research focused on cellular How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research

Angers established his independent research program in the Department of Pharmaceutical Sciences at the He is the recipient of the Canada Research Chair in Functional Architecture of Signal Transduction. His research program is developed to understand the signaling mechanisms underlying the Wnt and Hedgehog development of novel antibody molecules blocking and activating the Wnt pathway for the treatment of cancers of Toronto, an internationally recognized Research Institute bringing together multidisciplinary teams

UK, Wellcome Trust, and the Medical Research Council. She obtained her PhD in 2012 from the University of Oxford, where her research focused on the cellular Caroline moved to the University of Birmingham in 2018 to establish her research group investigating Her current research focuses on how metabolic GPCRs cross-talk and interact to regulate appetite and working on the study of membrane trafficking processes in pancreatic beta cells before returning to the UK

GPCR is to accelerate GPCR drug discovery by sharing the latest research and technology advances in the My experience in basic research at several universities worldwide and early R&D at Novo Nordisk A/S allowed Trejo’s research program is to gain a thorough and mechanistic understanding of processes that control cell signaling by protease-activated receptors (PARs) and the impact on vascular inflammation and cancer , and cancer and is an important drug target.

professor and chair of the Department of Computational and Quantitative Medicine (DCQM) at the Beckman Research She is also the Associate Director of the City of Hope Comprehensive Cancer Center. Dr. Vaidehi joined the Beckman Research Institute of the City of Hope in 2006 as a Professor and became chair How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research

Caroline Formstone Abstract "Breast cancer is the most common form of cancer amongst women. Biochemistry and Molecular Biology, University of New Mexico" About Jianxiang Xue "I am a postdoctoral researcher Alcohol Abuse and Alcoholism, National Institutes of Health, Rockville, MD, USA" About Bill Huang "Researcher I completed my Master’s thesis on ADGRL3, where I conducted research involving mammalian cell cultures Currently, my research focuses on the intracellular signaling of ADGRL3 from a single-molecule perspective

medicine cluster in Copenhagen and at the Institute of Biological Psychiatry in Roskilde working with the UK Alexander had a research sabbatical with Madan Babu at the MRC Laboratory of Molecular Biology in Cambridge , UK, where he was working on the impact of genetic variations on drug response. He received the “HC Ørsted Research talent prize” and “Bayer Pharmaceuticals Ph.D. How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research

My research aims to understand the mechanisms and consequences cell communication via heterotrimeric Our ongoing efforts have direct implications in cancer, embryonic development defects, and neurological Garcia-Marcos shares insights on transitioning from postdoctoral research to leading his own lab, addressing Garcia-Markos reflects on milestones in his research journey, reinforcing the passion that drives scientists How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research